Agenus (AGEN) Net Income towards Common Stockholders (2010 - 2026)

Agenus' (AGEN) quarterly Net Income towards Common Stockholders came in at $39.2 million in Q1 2026, up 254.71% year-on-year from $11.0 million in Q1 2025, and up 468.43% quarter-over-quarter from -$10.6 million in Q4 2025.

Agenus (AGEN) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Agenus' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $39.2 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 254.71% year-over-year to $39.2 million in Q1 2026; TTM through Mar 2026 was $64.4 million, a 133.75% increase from a year earlier, with the FY2025 full-year figure at -$101000.0, up 99.96% from the prior year.
  • Net Income towards Common Stockholders climbed to $39.2 million in Q1 2026 per AGEN's latest filing, from -$10.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $63.9 million in Q3 2025 and bottomed at -$71.1 million in Q4 2022.
  • The 5-year median for Net Income towards Common Stockholders is -$48.4 million (2022), against an average of -$38.5 million.
  • Across the five-year window, Net Income towards Common Stockholders tumbled 130.41% in 2022 and surged 254.71% in 2026, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$71.1 million in 2022, then surged by 34.86% to -$46.3 million in 2023, then grew by 0.93% to -$45.9 million in 2024, then surged by 76.84% to -$10.6 million in 2025, then soared by 468.43% to $39.2 million in 2026.
  • Per Business Quant, the three latest AGEN Net Income towards Common Stockholders figures stand at $39.2 million (Q1 2026), -$10.6 million (Q4 2025), and $63.9 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -625.73
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -0.68
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 366.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -453.82 Mn
10 Agenus 222.90 Mn 222.90 Mn 33.74 Mn 39.17 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 39.17 Mn
Dec 31, 2025 -10.63 Mn
Sep 30, 2025 63.86 Mn
Jun 30, 2025 -28.01 Mn
Mar 31, 2025 -25.32 Mn
Dec 31, 2024 -45.91 Mn
Sep 30, 2024 -66.44 Mn
Jun 30, 2024 -53.14 Mn
Mar 31, 2024 -61.94 Mn
Dec 31, 2023 -46.34 Mn
Sep 30, 2023 -62.25 Mn
Jun 30, 2023 -69.07 Mn
Mar 31, 2023 -68.31 Mn
Dec 31, 2022 -71.15 Mn
Sep 30, 2022 -54.28 Mn
Jun 30, 2022 -46.49 Mn
Mar 31, 2022 -48.38 Mn
Dec 31, 2021 -65.56 Mn
Sep 30, 2021 178.50 Mn
Jun 30, 2021 -83.34 Mn